Aug 27, 2015
France's bid to regain its influence reveals how far Europe is from fully achieving regulatory convergence, writes Reflector.
Aug 26, 2015
A recent poll reported that most Americans think drug prices are unreasonably high, but that 76% of Republicans prefer market competition over government regulation to lower prices. Stephen Littlejohn imagines what Donald Trump would say on the matter.
Aug 25, 2015
By Pharmaceutical Executive Editors
A new trade expo survey predicts that it is full speed ahead for a market now too big to be ignored, writes Cameron Sharp.
Aug 13, 2015
FDA needs to expand and empower its Office of Health & Constituent Affairs and its Patient Liaison Program to better coordinate interactions with individuals and physicians seeking expedited access to experimental therapies, writes Jill Wechsler.
Aug 13, 2015
Pharmaceutical Executive
The big data revolution offers great promise for drug development versus the traditional ways of bringing medicines to market, but there is a larger issue at stake: how to turn data quantity into data quality. William Looney reports.
Aug 06, 2015
As was the case decades ago, the “drug line” continues to be a major, if not the primary, concern of Medicaid administrators across the nation.
Aug 05, 2015
Pharmaceutical Executive
Despite overwhelming House approval last month of the 21st Century Cures Act, bipartisan support may fall apart in the coming months, writes Jill Wechsler.
Aug 04, 2015
Come fall, Boeing employees in St. Louis and South Carolina will get a new coverage alternatives in addition to their Blue Cross and Blue Shield plans.
Jul 31, 2015
The American Medical Association invested heavily in DC influence in the first two quarters of 2015. PhRMA wasn't far behind. Casey McDonald reports.
Jul 24, 2015
With biopharma companies increasingly accused of bankrupting the health care system with high prices, news that ICER has received a $5.2 million grant to expand its analyses of drug cost-effectiveness could be a game changer, writes Jill Wechsler.